Study shows experimental drug cuts stroke risk
BARCELONA, Spain — An experimental drug reduces the stroke risk in patients with irregular heartbeats by nearly four times, compared with the popular drug warfarin — but possibly at a cost, according to new research released Sunday.
Patients taking the new drug dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim, also were slightly more likely to have heart attacks or stomach pain, according to the research presented at the European Society of Cardiology meeting in Barcelona.
Patients with irregular heartbeats are up to 17 times more likely to have a stroke than healthy people.
About one-sixth of all strokes occur in patients with irregular heartbeats who also have other risk factors such as smoking or obesity. In the United States, there are about 2 million people with such a condition.
Until now most such patients have been given warfarin, which has been around since the 1950s and has side effects including bleeding risks and requires lifestyle changes such as dietary restrictions.
Doctors hope the new drug can help improve treatment for patients, who must be monitored continuously if they are put on warfarin and avoid alcohol and foods such as spinach and cranberries.
The new research on dabigatran — which has not yet been approved by any drug regulatory agency — was compiled after doctors monitored more than 18,000 patients with irregular heartbeats, or atrial fibrillation, worldwide for about two years starting in 2005. The patients took either dabigatran or warfarin, at varying doses.
On warfarin a patient’s risk of stroke drops dramatically to about 0.38 percent per year, according to the study, also published online in the New England Journal of Medicine. Warfarin has invited complications, however, because it is difficult to dose and may be confusing for patients to take, doctors have said.
On dabigatran, that risk is slashed even further to about 0.10 percent per year, the study says.
“It is certainly a big step forward,” said Dr. Fausto Pinto, director of the Cardiovascular Institute at the University of Lisbon, Portugal, and program chairman of the European Society of Cardiology.
Dabigatran “probably will replace warfarin,” as it is easier for both doctors and patients to use, said Pinto, who was not involved in the study.
Last year, the market for anti-clotting drugs was about $13.6 billion globally.
Getting approval for dabigatran could take years after Boehringer Ingelheim submits data to regulatory agencies.
Dr. Clyde Yancy, medical director of the Baylor Heart and Vascular Institute in Dallas and president of the American Heart Association, said more information was needed on why dabigatran appeared to slightly increase the number of heart attacks, but that overall the data were encouraging.
“Patients have wanted something easier to take for their atrial fibrillation for years, and this may be it,” Yancy said. “That’s why this may be a game-changer.”
____
On the Net:
www.escardio.org
www.nejm.org
Related News
Fighting cocaine addiction with vaccine-like shots shows promise in government-funded researchOctober 5th, 2009 Vaccine-like shots help fight cocaine addictionCHICAGO — Vaccine-like shots to keep cocaine abusers from getting high also helped them fight their addiction in the first successful rigorous study of this approach to treating illicit drug use. The shots didn't work perfectly, but the researchers say their limited success is promising enough to suggest the intriguing vaccine approach could be widely used to treat addiction within several years.
Catalyst says it sees evidence its drug vigabatrin is effective despite failures; study surgesOctober 1st, 2009 Catalyst plans more tests of anti-addiction drugNEW YORK — Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective.
Study: Half of drug addicts quit after 6 months of treatment, but long-term care neededOctober 1st, 2009 Half of addicts quit after 6 months of treatmentLONDON — About half of heroin and crack cocaine addicts in England's treatment programs quit the drugs after six months, a new study says. Experts warned, however, that the danger of relapse means permanently kicking the habit probably requires ongoing care.
US regulators subpoena documents of brain disease with drugmaker Elan's TysabriSeptember 30th, 2009 US feds subpoena Elan for brain virus reportsWASHINGTON — U.S. financial regulators are demanding drugmaker Elan Corp.
Notable dates in the AIDS epidemicSeptember 24th, 2009 Notable dates in the AIDS epidemicKey dates in the AIDS epidemic:
—June 5, 1981: The U.S. Centers for Disease Control and Prevention reports five gay men in Los Angeles are suffering from a rare pneumonia found in patients with failing immune systems.
Study: Heart patients who get the flu are more likely to have a heart attackSeptember 21st, 2009 Study: Flu viruses can spark heart attacksLONDON — Heart patients who catch the flu may have more to worry about than just a fever or the sniffles: the virus could also spark a heart attack, new research shows. Amid the global outbreak of swine flu, experts say it's crucial that heart patients get vaccinated against both regular flu and swine flu to avoid medical problems.
Study: New, unlicensed swine flu treatment could help patients with Tamiflu-resistant virusesSeptember 3rd, 2009 Study: New treatment may combat drug-resistant fluLONDON — A new and unlicensed treatment for swine flu could be used in patients who have Tamiflu-resistant viruses, doctors say. In an article published Friday in the medical journal Lancet, British doctors describe how they used an intravenous form of the antiviral Relenza to treat a 22-year-old woman who had a severe case of swine flu.
New anti-clotting drug reduces heart patients' chances of dyingAugust 30th, 2009 New drug reduces risks for heart patientsBARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared to the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008.
AstraZeneca says Brilinta anti-clotting drug reduces chance of dying better than PlavixAugust 30th, 2009 New AstraZeneca drug reduces heart patients' risksBARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008.
Drugmaker Bristol Myers Squibb says to buy Medarex for $2.1B in cashJuly 23rd, 2009 Bristol Myers says to buy Medarex for $2.1BNEW YORK — Drugmaker Bristol-Myers Squibb Co. said Wednesday it is buying Medarex Inc.
Contrave - Weight-Loss Drug Trials Meet GoalsJuly 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss
in three late-stage clinical trials according to Associated Press reports.
Merck, Portola Pharmaceuticals sign deal worth up to $470 million to develop anticlotting drugJuly 9th, 2009 Merck, Portola in $470M deal for anticlotting drugTRENTON, N.J. — Merck & Co.
Experimental drug helps rabbits, monkeys survive anthrax infections; may aid people in attackJuly 8th, 2009 Drug gives anthrax protection in animal studiesNEW YORK — An experimental drug helped monkeys and rabbits survive anthrax in a series of studies, suggesting it could be useful in case of another anthrax attack. In 2001, five people died after inhaling anthrax germs they'd gotten through the U.S.
ARYx shares fall on failed late-stage study for potential blood clot drug tecarfarinJuly 8th, 2009 ARYx shares fall on failed late-stage studyNEW YORK — Shares of ARYx Therapeutics Inc. plunged Wednesday after the biotechnology company said its experimental anticoagulant tecarfarin failed to meet a key treatment goal in a late-stage study.
FDA tells parents to keep children on ADHD drugs, despite new evidence of sudden death risksJune 15th, 2009 FDA urges caution in weighing risks of ADHD drugsWASHINGTON — Federal health regulators are urging parents to keep their children on attention deficit drugs like Ritalin and Adderall, despite new evidence from a government-backed study that the stimulants can increase the risk of sudden death. Published Monday in the American Journal of Psychiatry, the study suggests a link between use of the stimulant drugs and sudden death in children and adolescents.
Loading ...